A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.

To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further trials of docetaxel in combination with a 5-day continuous infusion of 5-fluorouracil (5-FU) in advanced or recurrent breast cancer patients who had been treated previously with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, M., Watanabe, T., Sasaki, Y., Ying, D. F., Omuro, Y., Katsumata, N., Narabayashi, M., Tokue, Y., Fujii, H., Igarashi, T., Wakita, H., Ohtsu, T., Itoh, K., Adachi, I., Taguchi, T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150334/
https://www.ncbi.nlm.nih.gov/pubmed/9667671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150334/
https://www.ncbi.nlm.nih.gov/pubmed/9667671

Ejemplares similares